Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2020 Financial Results and Corporate Update
October 29 2020 - 08:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
clinical-stage biotechnology company focused on the development of
novel therapies with the potential to improve the lives of patients
with immune-mediated diseases, will host a conference call at 8:00
a.m. ET on Thursday, November 5, 2020, to discuss financial results
for the quarter ended September 30, 2020, and provide a corporate
update.
The dial-in numbers are (866) 211-4098 for domestic callers and
(647) 689-6613 for international callers. The Conference ID number
is 5472726. Due to the expected high demand on our conference
provider, please plan to dial in to the call at least 15 minutes
prior to the start time.
A live webcast of the conference call will also be available on
the investor relations page of the company’s corporate website at
https://ir.aldeyra.com. After the live webcast, the event will
remain archived on the Aldeyra Therapeutics website for 90
days.
About Aldeyra Therapeutics Aldeyra Therapeutics is a
clinical-stage biotechnology company focused on the development of
novel therapies with the potential to improve the lives of patients
with immune-mediated diseases. Two of the company’s lead compounds,
reproxalap and ADX-629, target reactive aldehyde species (RASP),
which are elevated in ocular and systemic inflammatory disease and
result in cytokine release via activation of a broad array of
inflammatory factors, including NF-κB, inflammasomes, and Scavenger
Receptor A. Reproxalap is being evaluated in Phase 3 clinical
trials in patients with dry eye disease and allergic
conjunctivitis. The company’s clinical pipeline also includes
ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing
for proliferative vitreoretinopathy, and ADX-1612, a chaperome
inhibitor in development for COVID-19 and ovarian cancer. For more
information, visit https://www.aldeyra.com/ and follow us on
LinkedIn, Facebook, and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029005225/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon Merrill
Associates, Inc. Tel: 617-542-5300 ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2023 to Mar 2024